About the Post

Author Information

Bilcare post net consolidated sales at Rs 856.02 cr; a growth of 32% for the year ended FY09

Pune, June 30, 2009: Bilcare Ltd., service provider to the pharmaceutical companies spanning across their value chain from drug discovery to market continues to expand and grow globally

The Consolidated Sales for the year ended FY09, stood at Rs 856.02 cr., - a growth of 31.6% over the previous year Consolidated Sales of Rs 650.68 cr.

This resulted in better EBIDTA of Rs 194.21 cr. for FY09 as against Rs 162.70 cr. for FY08, - a growth of 19.4%.

The India standalone Sales for FY09, stood at Rs 471.33 cr. as against Rs 406.35 cr. in FY08 recording a stable growth of 16% with the EBIDTA levels remaining constant and net profits being marginally lower.

The sales growth overseas was at 96% as compared to India with EBIDTA being more than 130%. While India will maintain a steady growth, the potential is in the overseas operations.
About Bilcare :

Headquartered in India, Bilcare is an integrated service provider to the global pharmaceutical sector across their value chain through its key business activities namely: Pharma Packaging Innovation, Global Clinical Services, Clinical Research Academy and Non-Clonable Technologies. These business activities encompass research, development, manufacturing and supply of products, processes, and services to the Pharma and Healthcare domain. Technologies business focuses on unique range of applications viz. security & product authentication, Track & Trace e-pedigree, medication compliance & Personalized Healthcare Management System. Bilcare operates state-of-the-art Manufacturing and Research facilities in India, Singapore, USA & UK and has regional offices in Brazil, Germany, China & Australia , while partnering with the global pharmaceutical sector by providing value solutions to address their key concerns i.e. counterfeit, compliance, cost communication and convenience.

Visit the publisher's website: http://www.bilcare.com

Comments are closed.